PDS Biotechnology Seeks Accelerated FDA Pathway for Cancer Therapy

Strategic Study Modification Proposed

PDS Biotechnology Corp has taken a decisive step in its regulatory strategy, potentially altering the trajectory for its lead immunotherapy candidate. The clinical-stage company has formally requested a meeting with the U.S. Food and Drug Administration to discuss an accelerated approval pathway for PDS0101, its investigational treatment for HPV16-positive head and neck cancer.

This regulatory move follows compelling final data from the VERSATILE-002 study, which demonstrated a median overall survival of nearly 40 months—a significant outcome in this challenging cancer indication. The company’s request, submitted on October 29, 2025, represents a strategic pivot that could substantially shorten the drug’s path to market.